Browsing Tag
FluCamp
2 posts
hVIVO (AIM: HVO) wins world-first Phase III whooping cough challenge trial contract with ILiAD Biotechnologies
hVIVO (AIM: HVO) signs its largest human challenge trial contract with ILiAD Biotechnologies for a world-first pivotal Phase III pertussis vaccine study. Read what it means for investors.
April 22, 2026
hVIVO engages in major phase 2b influeness drug study as exclusive UK clinical site
hVIVO plc (AIM & Euronext: HVO), a rapidly expanding specialist contract research organisation (CRO) renowned for its expertise…
July 7, 2024